Penumbra, Inc. Reports Third Quarter 2026 Financial Results
PR Newswire•29/10/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $410.1 million, up 15.6% year over year
- ➤Global thrombectomy revenue $279.2 million, up 18.1% year over year
- ➤Net income $42.3 million versus $45.9 million in Q3 2025
- ➤Pending Boston Scientific acquisition ends 2026 guidance and earnings call
Penumbra, Inc. Reports Third Quarter 2026 Financial Results PR Newswire
ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.